Oritavancin
Antimicrobial / ClinicalAlso known as: Orbactiv
Mechanism
A remarkable single-dose antibiotic that can treat an entire skin infection with just one IV infusion. It has three killing mechanisms (cell wall synthesis inhibition, membrane disruption, and blocking crosslinking). Its incredibly long half-life (~245 hours / ~10 days) means the drug keeps working in your body for weeks after a single dose. Ideal for patients who can't take daily antibiotics.
Technical detail
Semisynthetic lipoglycopeptide — vancomycin derivative with N-alkyl-p-chlorophenylbenzyl substituent on disaccharide and 4'-chlorobiphenylmethyl group. Triple mechanism of action: (1) inhibits transglycosylation by binding D-Ala-D-Ala on lipid II (AND D-Ala-D-Lac — active against VanA VRE), (2) inhibits transpeptidation by binding pentaglycine bridge crosslinks, (3) disrupts membrane integrity via lipophilic side chain insertion. Extremely long half-life: 245 hours (allows single-dose therapy). Single 1200 mg IV infusion over 3 hours for acute bacterial skin and skin structure infections (ABSSSI). Clinical cure rates: 82.3% (SOLO I trial). Bactericidal against MRSA, MSSA, VRE (including VanA phenotype), streptococci. Cannot use unfractionated heparin for 120 hours post-dose (interferes with aPTT assay).
Effects
ANTIMICROBIAL MECHANISM: Semi-synthetic lipoglycopeptide derived from chloroeremomycin (vancomycin class). Triple mechanism of action: (1) Binds D-Ala-D-Ala on peptidoglycan precursors (like vancomycin), blocking transpeptidation. (2) Also binds the pentaglycine cross-bridge segment of peptidoglycan, inhibiting transglycosylation — this is unique among glycopeptides. (3) The lipophilic 4'-chlorobiphenyl side chain anchors in the cell membrane, disrupting membrane integrity and causing depolarization. This triple mechanism makes oritavancin rapidly bactericidal (unlike vancomycin which is slowly bactericidal) and active against many vancomycin-resistant strains. SPECTRUM: MRSA (MIC90 0.06 μg/mL — extremely potent), MSSA, heterogeneous VISA (hVISA), VISA (MIC 4-8 μg/mL for vancomycin — oritavancin retains activity), VanB-type VRE. Retains some activity against VanA-type VRE due to the membrane disruption mechanism and pentaglycine bridge binding (MIC 0.5-2 μg/mL, vs. vancomycin MIC >256). Streptococci, C. difficile (in vitro). MIC BREAKPOINTS: FDA breakpoint S. aureus: susceptible ≤0.12 μg/mL (most potent breakpoint of any glycopeptide). No Gram-negative activity. RESISTANCE MECHANISMS: Resistance development appears very difficult due to triple mechanism. VanA-type VRE shows reduced susceptibility but not frank resistance. No established resistance mechanism described to date (as of 2026). Cross-resistance with other glycopeptides is incomplete due to additional mechanisms. PHARMACOKINETICS: Ultra-long half-life ~245 hours (10.2 days), enabling single-dose therapy. High protein binding (85%). Vd ~1.3 L/kg (larger than dalbavancin — better tissue distribution). Eliminated primarily via slow excretion in feces and urine. No hepatic metabolism. No dose adjustment for renal or mild-moderate hepatic impairment. Achieves sustained bactericidal concentrations in skin and soft tissue for >2 weeks after single dose. TOXICITY: Well tolerated. Most common: headache, nausea, vomiting, limb and subcutaneous abscess, diarrhea. Infusion-related reactions in ~2% (less than vancomycin). CRITICAL INTERACTION: Oritavancin inhibits and induces CYP enzymes and is a weak inhibitor of CYP2C9 and CYP2C19. Interferes with coagulation assays (falsely prolongs aPTT for 48 hours and INR for 24 hours) — this is clinically important. Cannot use unfractionated heparin for 48 hours after oritavancin (cannot monitor aPTT). Use LMWH or DOACs if anticoagulation needed.
Practitioner Guide
CLINICAL PEARLS — INFECTIOUS DISEASE SPECIALIST PERSPECTIVE: DOSING: FDA-approved: 1200 mg IV single dose for ABSSSI. That is the entire treatment — one infusion. Infuse over 3 hours in 1000 mL D5W (NOT saline — oritavancin precipitates in saline). OFF-LABEL DOSING: For bone/joint and deeper infections — some ID specialists use repeat dosing: 1200 mg IV weekly or q2weeks. Limited data but growing case series support this approach. THE SINGLE-DOSE ADVANTAGE: Like dalbavancin, oritavancin excels for patients with adherence challenges (substance use disorder, homelessness, psychiatric illness). One observed infusion = complete treatment for uncomplicated ABSSSI. No PICC line, no follow-up infusions, no oral step-down needed. THE COAGULATION ASSAY PROBLEM: This is the #1 practical limitation. Oritavancin artificially prolongs aPTT for ~48 hours and INR for ~24 hours. This means: (1) You cannot monitor unfractionated heparin (aPTT-based monitoring) for 48 hours after dosing. (2) INR monitoring for warfarin is unreliable for 24 hours. (3) If a patient develops a VTE or PE after oritavancin, you cannot use aPTT-monitored heparin — use LMWH (anti-Xa monitored) or DOACs instead. (4) Communicate this to the ED and hospitalist team. SALINE INCOMPATIBILITY: Oritavancin MUST be diluted in D5W. Precipitates in saline. Flush IV line with D5W before and after infusion. This is a source of errors — ensure pharmacy and nursing are aware. WHEN TO CHOOSE ORITAVANCIN VS. DALBAVANCIN: Oritavancin advantages: true single dose (dalbavancin requires 2 visits for 2-dose regimen, though single-dose 1500 mg is now approved). Better activity against VanA VRE and VISA. Faster bactericidal activity. Dalbavancin advantages: no coagulation assay interference. Compatible with saline. Longer half-life (14 vs. 10 days). More off-label data. Both: excellent tolerability, no renal dosing, no TDM needed. MONITORING: No drug level monitoring needed. No routine CPK (unlike daptomycin). Baseline and periodic CBC, CMP reasonable. Be aware of coagulation assay interference. If patient needs surgery within 48 hours — alert surgical team about aPTT prolongation (artifact, not true coagulopathy). COMBINATION THERAPY: Limited data. In vitro synergy with rifampin and gentamicin. Some ID specialists use oritavancin as a "backbone" for complex infections and add oral agents (rifampin, TMP-SMX) for biofilm penetration.
Research Summary
TIER 1 (Gold Standard): Corey et al., 2014 (SOLO I & II) — Phase III RCTs demonstrating non-inferiority of single-dose oritavancin vs. 7-10 days of vancomycin for ABSSSI (NEJM, PMID: 24897081 and Clinical Infectious Diseases). FDA-approved 2014. EMA-approved 2015. TIER 2 (Strong): Mendes et al., 2012 — in vitro activity against Gram-positive pathogens including VISA and VRE (Antimicrobial Agents and Chemotherapy). Zhanel et al., 2012 — comprehensive pharmacology review (Drugs). DrugBank DB04911. IDSA/SHEA ABSSSI guidelines. PK/PD data supporting the ultra-long dosing interval. TIER 3 (Moderate): Case series for off-label indications: prosthetic joint infections, osteomyelitis, bacteremia. Real-world experience from emergency departments using single-dose oritavancin for ABSSSI (multiple published case series). Conference presentations at IDWeek, ECCMID. International data from European clinical experience. Practitioner tips on managing the coagulation assay interference (multiple published commentaries and clinical pearls). KEY FINDINGS: (1) True single-dose cure for uncomplicated ABSSSI — paradigm shift. (2) Triple mechanism provides activity against VISA and VanA VRE. (3) Coagulation assay interference is the main practical limitation. (4) Cannot use saline — D5W only. (5) Growing off-label use mirrors dalbavancin trajectory. GAPS: Phase III trials for deep-seated infections. Head-to-head vs. dalbavancin. Optimal repeat dosing for osteomyelitis/endocarditis. Long-term safety of repeated dosing. Whether triple mechanism translates to clinical superiority over other glycopeptides. ACTIVE TRIALS: Multiple Phase IV and investigator-initiated trials for expanded indications.